Carmit Strauss

Benefit-Risk Balance for Medicinal Products: Report Summary from the Council for International Organizations of Medical Sciences (CIOMS) Working Group XII.

PURPOSE Benefit-risk assessment (BRA) is a foundation of regulatory decision making and clinical practice for medicinal products. Although historically assessments relied on expert judgment and narrative summaries, over time, expectations have shifted toward approaches that are more structured, transparent, and patient...